Entered into an Agreement to be acquired by QOL MedicalNet product sales for the third quarter of 2025 reached $4.3 million; ...
Total revenues in the first nine months of the year were $420 million, a 24% increase from the same period last year Product and service revenue increased by 85%, to $237 million in the first nine mon ...
44m
Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights
Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company advancing its lead Investigational New Drug ("IND") candidate, SER-252, for advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback